The risk of developing a blood clot from a COVID-19 vaccine is extremely low. For most people, the benefit of protection against severe COVID-19 far outweighs this rare risk. The specific type of clot linked to some vaccines is a unique condition called Vaccine-Induced Immune Thrombotic Thrombocytopenia (VITT), which requires specific treatment and is different from common blood clots.
What Exactly Is the Blood Clot Risk Linked to the COVID Vaccine?
The blood clot risk is tied to two specific viral vector vaccines: the AstraZeneca and Johnson & Johnson (Janssen) vaccines. These vaccines use a modified cold virus to deliver instructions to your cells. They are not the mRNA vaccines from Pfizer or Moderna, which have not been linked to this specific clotting condition.
Health agencies worldwide identified this rare side effect in early 2021. The risk is highest in women under 50 years old. For this group, the risk of developing VITT is roughly 1 in 100,000 to 1 in 200,000 doses given. For men and older women, the risk is even lower, closer to 1 in 500,000 or less.
It is important to understand that these numbers are estimates from global surveillance systems. The exact rate varies by country and reporting method. However, all estimates place the risk as very rare when compared to the risks of severe illness from COVID-19 itself.
How Does the Vaccine Cause a Blood Clot?
VITT is not a typical blood clot. It involves two things happening at once: a low platelet count and a clot in an unusual location, often the brain’s venous sinuses (cerebral venous sinus thrombosis) or in the abdomen.
Platelets are cells that help your blood clot. In VITT, the body makes antibodies that activate the platelets. This causes platelets to clump together and form clots, while also being consumed. That is why platelet counts drop even as clots form.
The antibodies are directed against a protein called Platelet Factor 4 (PF4). This is the same mechanism behind a rare complication of the blood thinner heparin called HIT (heparin-induced thrombocytopenia). The key difference is that VITT happens without any prior heparin exposure.
This is why treatment matters so much. Giving heparin, the standard blood thinner, can make VITT worse. Doctors now know to use alternative blood thinners and intravenous immunoglobulin (IVIG) to treat this specific condition.
What Are the Symptoms of a Vaccine-Related Blood Clot?
Symptoms appear between 4 and 28 days after vaccination. This timing is a critical clue. A clot that happens weeks after vaccination is more likely related to the vaccine than one that happens months later.
Watch for these warning signs:
- Severe or persistent headache that does not improve with pain relievers
- Blurred vision or difficulty speaking
- Shortness of breath or chest pain
- Swelling, pain, or redness in a leg or arm
- Severe abdominal pain
- Easy bruising or tiny red spots under the skin (petechiae)
A mild headache after vaccination is common and not a concern. The headache associated with VITT is different. It is severe, unrelenting, and often worse when lying down. It does not respond to normal headache medication.
If you experience any of these symptoms within a month of receiving a viral vector vaccine, seek medical attention immediately. Tell the doctor which vaccine you received and when. This information helps them run the correct tests, including a platelet count and a test for anti-PF4 antibodies.
Which Vaccines Are Linked to This Condition?
Only the adenoviral vector vaccines have been linked to VITT. These include:
- AstraZeneca (Vaxzevria and Covishield)
- Johnson & Johnson (Janssen)
The mRNA vaccines — Pfizer-BioNTech and Moderna — have not been associated with VITT. Large-scale safety monitoring studies have found no increased risk of this specific clotting disorder with mRNA vaccines.
It is also worth noting that the risk of blood clots from COVID-19 infection itself is much higher than the risk from any vaccine. Studies consistently show that COVID-19 infection increases the risk of clotting disorders by several times, particularly in the weeks following infection. This includes both common deep vein thrombosis and the rare cerebral venous sinus thrombosis.
The viral vector vaccines are no longer widely used in the United States. The Johnson & Johnson vaccine was paused in April 2021 to investigate these cases and later had its authorization restricted. The AstraZeneca vaccine was never authorized for use in the US. However, both remain in use in other countries, which is why this information remains relevant.
Who Is at Higher Risk?
Age and sex are the two main risk factors. Women under 50 have the highest relative risk. The reasons for this are not fully understood.
Hormonal factors may play a role. Estrogen influences blood clotting, and younger women may also be taking oral contraceptives or hormone replacement therapy. However, no study has confirmed that these medications increase VITT risk specifically.
Having a personal or family history of blood clots does not appear to increase the risk of VITT. This is different from other types of blood clots where such history matters. VITT is an immune-mediated reaction, not a typical clotting disorder.
There is no screening test to predict who will develop VITT. Blood tests done before vaccination cannot identify people at risk. This is why the medical community relies on symptom awareness and prompt treatment rather than prevention.
How Is VITT Treated?
Treatment for VITT differs from standard clot treatment. The first step is avoiding heparin. Standard protocols for treating blood clots often start with heparin, but in VITT this can worsen the condition.
Doctors treat VITT with non-heparin blood thinners such as argatroban, bivalirudin, or fondaparinux. They also give intravenous immunoglobulin (IVIG) to block the harmful antibodies and stop platelet activation.
Early treatment improves outcomes significantly. One study found that mortality rates dropped from about 40% in the early months of the outbreak to under 10% once doctors understood how to treat the condition properly. This improvement is due to faster recognition and better treatment protocols.
Most patients who receive prompt treatment recover fully. The condition is serious and can be fatal if untreated, but it is treatable when identified quickly.
What Should You Do If You Already Had a Viral Vector Vaccine?
If you received a viral vector vaccine months or years ago, there is no current concern. The risk window for VITT is within 4 to 28 days after vaccination. If you are well past that window, you are not at risk from that dose.
If you received the vaccine recently and are within that window, remain alert for symptoms. Most people who develop VITT do so within the first two weeks. The condition is rare, and most people who receive these vaccines do not develop any serious side effects.
For future booster doses, the mRNA vaccines are the standard recommendation in the US. The CDC and FDA no longer recommend the Johnson & Johnson vaccine for any age group due to the VITT risk and the availability of safer alternatives.
If you have concerns about your vaccine history, discuss them with your healthcare provider. They can review your records and advise you on any next steps based on your specific situation.
How Does This Risk Compare to COVID-19 Itself?
The comparison is not close. COVID-19 infection carries a much higher risk of blood clots than any vaccine. Studies show that COVID-19 increases the risk of venous thromboembolism by several times compared to baseline. The risk is highest in severe cases but exists even in mild infections.
COVID-19 also causes clots in the lungs, heart, and brain. It can cause long-term damage to blood vessels. The vaccine-related VITT is extremely rare and treatable. The clot risk from infection is common and can be fatal.
For this reason, public health agencies worldwide continue to recommend vaccination. The risk-benefit calculation strongly favors vaccination for nearly everyone, including younger women who have the highest VITT risk.
The one exception is people who have already developed VITT after a first dose. These individuals should not receive another dose of a viral vector vaccine. They may still be able to receive an mRNA vaccine after discussing it with their doctor, though specific guidance varies by country.
Frequently Asked Questions
How long after the COVID vaccine can a blood clot occur?
Blood clots from the vaccine typically occur between 4 and 28 days after vaccination. Clots that happen outside this window are unlikely to be related to the vaccine.
Can the Pfizer or Moderna vaccine cause blood clots?
No large-scale studies have found a link between mRNA vaccines and the specific clotting condition VITT. These vaccines are not associated with the rare blood clot risk seen with viral vector vaccines.
What should I do if I have a severe headache after the COVID vaccine?
Seek medical attention if you have a severe, persistent headache within a month of receiving a viral vector vaccine. Tell the doctor which vaccine you received and when, so they can test for VITT if needed.
Is it safe to get a COVID vaccine if I have a history of blood clots?
A history of blood clots does not appear to increase the risk of VITT. The mRNA vaccines are considered safe for people with a history of clotting disorders, and your doctor can help you decide which vaccine is right for you.
